Floatz logo

Ratg

Myelodysplastic Syndrome

Memorial Sloan Kettering Cancer CenterPhase 3Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
36/ 100
Competitive Position
73/ 100

Competitive context

107 Active assets in the Myelodysplastic Syndrome cohort.

Asset / SponsorPhaseRating
Thiotepa
Sawa Ito, MD
Phase 4BB
Fludarabine
Sawa Ito, MD
Phase 4BB
Cladribine
University of Florida
Phase 2/3BB
Clofarabine
Memorial Sloan Kettering Cancer Center
Phase 2/3BB
Treosulfan
Masonic Cancer Center, University of Minnesota
Phase 3BB

View all 50 →

Same molecule, other indications

Ratg is also rated in:

Acute Myelogenous LeukemiaDormant
CCC
Indicative ·
51 / 100
View asset →
Chronic Myelogenous LeukemiaDormant
CC
Indicative ·
47 / 100
View asset →
acute myeloid leukemiaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →